Treatment of obesity through the inhibition of CaMKII
- Summary
- During nutrient deprivation, the liver produces glucose through a process known as hepatic glucose production (HGP). Excessive glucose production via HGP is thought to play a role in the high blood glucose levels observed in patients suffering from obesity and type II diabetes. The enzyme CaMKII, which has previously been linked to Alzheimer’s disease and heart arrhythmia, has been shown to play a role in the signaling pathway that causes HGP. This technology provides a method to treat obesity and related metabolic disorders by reducing the activity of CaMKII, and consequently, HGP and blood glucose levels.
- Technology Benefits
- Unique therapeutic target that is distinct from currently marketed medicationsCan be used in addition to other obesity and diabetic treatmentsWell characterized animal models Patent Information:Patent Pending (US 20140314789)Tech Ventures Reference: IR CU12060
- Technology Application
- Development of drugs that inhibit CaMKII to treat obesity and associated metabolic disorders (e.g. type II diabetes)Target for treatment of heart arrhythmiasWeight loss supplement in addition to diet and exercise
- Detailed Technology Description
- None
- *Abstract
-
None
- *Inquiry
- Joan MartinezColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
- *IR
- CU12060
- *Principal Investigator
-
- *Publications
- Ozcan L, Wong CCL, Li G, Xu T, Pajvani U, Park SKR, Wronska A, Chen BX, Marks AR, Fukamizu A, Backs J, Singer HA, Yates JR III, Accili D, Tabas I, “Calcium Signaling through CaMKII Regulates Hepatic Glucose Production in Fasting and Obesity” Cell Metabolism. 2012 May 2;15(5):739-751.
- Country/Region
- USA
For more information, please click Here
